Who are CUCART19's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): COVAX only (1st and 2nd dose), Novavax recombinant protein vaccine, AntiCov-220, Ad26.COV2.S vaccine, CCP, Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cucart19.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CUCART19 — Competitive Intelligence Brief

CUCART19 (CUCART19) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Infectious Disease.

phase 2 Monoclonal antibody SARS-CoV-2 spike protein Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

CUCART19 (CUCART19) — Chi Kong Li. CUCART19 is a monoclonal antibody targeting the SARS-CoV-2 spike protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CUCART19 TARGET	CUCART19	Chi Kong Li	phase 2	Monoclonal antibody	SARS-CoV-2 spike protein
COVAX only (1st and 2nd dose)	COVAX only (1st and 2nd dose)	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
Novavax recombinant protein vaccine	Novavax recombinant protein vaccine	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Recombinant protein vaccine	Viral surface antigens (e.g., SARS-CoV-2 spike protein)
AntiCov-220	AntiCov-220	Nguyen Thi Trieu, MD	marketed	Monoclonal antibody	SARS-CoV-2 spike protein
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein
CCP	CCP	Metro Infectious Disease Consultants	marketed	Convalescent plasma	SARS-CoV-2 spike protein and other viral antigens
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)	tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CUCART19 — Competitive Intelligence Brief. https://druglandscape.com/ci/cucart19. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab